BREAKTHROUGH: breast cancer patients may skip chemo thanks to new drug combo

NCT ID NCT07237256

Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called ribociclib can safely replace chemotherapy for women with a common type of early breast cancer (HR+ HER2-). About 3,900 women at intermediate risk of recurrence will receive either standard hormone therapy plus ribociclib or hormone therapy plus chemotherapy. The goal is to see if skipping chemotherapy reduces side effects without lowering the chance of staying cancer-free.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 3,902 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2037

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient must have signed a written informed consent prior to any trial-specific screening procedure. Note: When the patient is physically unable to give their written consent, an impartial witness of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent. 2. Patient is ≥ 18 years old. 3. Patient is female with known menopausal status at the time of randomization. Post-menopausal status is defined as: 1. Patient underwent bilateral oophorectomy, or 2. Age ≥ 60 years, or 3. Age \< 60 years and either amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression) or Follicle-stimulating hormone (FSH) and plasma estradiol are in the postmenopausal ranges per local normal ranges. 4. If taking tamoxifen or toremifene and age \<60 years, then FSH and plasma estradiol level in postmenopausal ranges. 4. The following criteria must be met for histologically confirmed invasive breast carcinoma, as determined by the local pathologist: 1. Pathological stage (8th edition of the AJCC), including pT2 pN0 Grade 3 or pT2 pN0 Grade 2 with Ki67≥20% or pT0-2 pN1 or pT3-4 pN0 2. ER-positive (with tumor cells showing ≥10% ER staining) and HER2-negative according to the most recent ASCO/CAP guidelines. Note: Multifocal and multicentric tumors are allowed if they meet the clinical stage II criteria of the 8th Edition of the AJCC. All tumors must be ER-positive and HER2-negative. Patients with bilateral invasive breast cancer (diagnosed simultaneously or within 6 months of each other) are eligible if all lesions tested on both sides are ER+ (ie, ≥10% positive stained cells) and HER2- AND adequate surgery has been performed in both breasts. 5. Chemotherapy eligible per investigator decision, based on clinicopathological findings or the results of any genomic signature. 6. Patient has no contraindication for the adjuvant endocrine therapy (ET) or chemotherapy in the trial and is planned to be treated with ET for 5 years (after randomization date) or more. 7. Curative surgery for the invasive disease must have been performed with negative surgical margins within 12 weeks before randomization. If positive surgical margins, patients are eligible if revision surgery or other adequate local treatment (i.e local radiotherapy) is planned. 8. Women of childbearing potential (CBP) must have a confirmed negative serum pregnancy test (β-hCG) before starting study treatment. 9. Women of childbearing potential must agree to use one effective form of contraception during trial treatment and up to 21 days after the last dose of study drugs or longer, if required per standard of care; 10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to randomization. 11. Adequate hematological, renal, and hepatic function, as outlined below: 1. Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L 2. Platelet count ≥100 x 10⁹/L 3. Hemoglobin ≥9 g/dL 4. Total bilirubin \< ULN. Patients with known Gilbert syndrome may be enrolled with total bilirubin ≤3 x ULN or direct bilirubin ≤1.5 x ULN 5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 x ULN 6. Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/min/1.73m² (CKD-EPI equation (2021)) 7. Potassium, total calcium (corrected for serum albumin), and magnesium should be within institutional normal limits or corrected to within normal limits using supplements before the first dose of study medication. 12. Standard 12-lead ECG values assessed, as: 1. QTcF interval (QT interval using Fridericia's correction) at screening \< 450 milliseconds (msec) 2. Resting heart rate 50-100 beats per minute (determined from the ECG) 13. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures. 14. Absence of any psychological, familial or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 15. Patients must be affiliated to a Social Security System (or equivalent) based on local regulations. Exclusion Criteria: 1. Patient has received any neoadjuvant chemotherapy since her breast cancer diagnosis or has received any prior CDK4/6 inhibitor. 2. Breast cancer diagnosed while patient was receiving tamoxifen, raloxifene or aromatase inhibitors (AIs) for reduction in risk ("chemoprevention") of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. 3. Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET (e.g. rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption, and soy or peanut allergy). 4. Patient with evidence or history of distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition), inflammatory breast cancer, breast cancer recurrence (local or distant) or a different primary breast cancer. 5. Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before randomization. Note: Patients with adequately treated basal or squamous cell skin carcinoma or curatively resected cervical cancer in situ are eligible. 6. Patients whose breast cancer is considered as endocrine therapy insensitive, as determined by investigator's opinion; this may include (but is not limited to) breast cancer classified as " basal like " by molecular signatures (if available in the patient file) and/or breast cancer with persistently high proliferation after pre-operative endocrine therapy. 7. Patient has had major surgery within 14 days prior to study treatment initiation. 8. Patient has known history of human immunodeficiency virus (HIV) infection (testing is not mandatory) whose antiretroviral therapy (ART) has a known strong CYP3A4 inhibitor with potential for DDI with ribociclib. Patients with HIV may be enrolled if they fulfil the criteria recommended by FDA and ASCO guidelines (FDA Guidance, Uldrick et al. 2017): 1. CD4+ T-cell (CD4+) counts ≥ 350 cells/µL, AND 2. No history of AIDS-defining opportunistic infections within the past 12 months (prophylactic antimicrobials allowed if no drug-drug interactions or overlapping toxicities), AND 3. On established ART which is not a strong CYP3A4 inhibitor, for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrolment. Effective ART is defined as a drug, dosage, and schedule associated with reduction and control of the viral load. 9. Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (testing is not mandatory). 10. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following: 1. History of documented myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft within 6 months prior to trial entry. 2. Documented cardiomyopathy. 3. Left Ventricular Ejection Fraction (LVEF) \< 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) (testing not mandatory) 4. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: * Risk factors for Torsades de Pointes (TdP) including uncorrected hypocalcemia, hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia. * Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause TdP that cannot be discontinued or replaced by safe alternative medication (e.g. within 5 half-lives or 7 days prior to starting trial treatment). * Inability to determine the QTcF interval. 5. Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade Atrioventricular (AV) block (e.g. bifascicular block, Mobitz type II and third degree AV block). 6. Uncontrolled arterial hypertension with systolic blood pressure \>160 mmHg. 11. Presence of any other medical conditions, including respiratory or metabolic dysfunction, physical examination findings, or laboratory results that raise reasonable suspicion of a contraindication to the use of an experimental drug, potential impact on compliance with the study protocol, influence on result interpretation, or increased risk of treatment complications for the patients (such as severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, preexisting Crohn's disease or ulcerative colitis, or a preexisting chronic condition resulting in clinically significant diarrhea). 12. Previous history of pneumonitis, regardless of cause. 13. Patient is currently receiving any of the following substances within 7 days before randomization and which cannot be stopped within seven days prior to the start of treatment: 1. Concomitant medications, herbal supplements, and/or fruits (e.g. grapefruit, pummelos, starfruit, Seville oranges) and their juices that are known as strong inhibitors or inducers of CYP3A4/5 2. Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 3. Any medication prohibited according to the instructions for goserelin, leuprolide or triptorelin (pre-menopausal patients), anastrozole, exemestane, letrozole, or ribociclib. 4. Medications known to have a risk of prolonging the QT interval or causing Torsades de Pointes. 14. Patient is concurrently using hormone replacement therapy. Estrogen replacement therapy discontinued less than two weeks prior to the start of treatment. 15. Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting trial treatment, or has not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: a short duration (\<5 days) of systemic corticosteroids; any duration of topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local injections (e.g. intra-articular). 16. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, liver cirrhosis or any other significant liver disease, active untreated or uncontrolled fungal, bacterial or viral infections, active infection requiring systemic anti-bacterial therapy, etc.) or limit life expectancy to ≤5 years. 17. Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational drug(s) (whichever is longer), or participation in any other type of medical research judged not to be scientifically or medically compatible with this trial. If the patient is enrolled or planned to be enrolled in another study that does not involve an investigational drug, the agreement of the sponsor is required to establish eligibility. 18. Inability or unwillingness to swallow oral pills. 19. Presence of malabsorption syndrome or any other condition that could hinder the absorption of study drugs in the gastrointestinal tract. 20. Any psychological, familial, sociological, or geographical factors that may impede adherence to the study protocol and follow-up schedule. 21. Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the first 48 months of adjuvant therapy. 22. Persons deprived of their liberty or under protective custody or guardianship.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

119 sites in 5 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

AGAPLESION Markus Krankenhaus
NOT_YET_RECRUITING

Frankfurt, 60431, Germany
AORN Sant'Anna e San Sebastiano
NOT_YET_RECRUITING

Caserta, 81100, Italy
Azienda Ospedaliero Universitaria Pisana
NOT_YET_RECRUITING

Pisa, 56100, Italy
Azienda Ospedaliero-Universitaria Federico II
NOT_YET_RECRUITING

Naples, 80131, Italy
CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologie
ACTIVE_NOT_RECRUITING

Plérin, France
CH Cholet
NOT_YET_RECRUITING

Cholet, 49300, France
CH Henri Mondor
ACTIVE_NOT_RECRUITING

Aurillac, 15000, France
CH Victor Dupouy
NOT_YET_RECRUITING

Argenteuil, 95107, France
CHI Fréjus St-Raphaël
ACTIVE_NOT_RECRUITING

Fréjus, France
CHU Bretonneau
NOT_YET_RECRUITING

Tours, 37000, France
CHU Grenoble
NOT_YET_RECRUITING

La Tronche, France
CHU Orléans
ACTIVE_NOT_RECRUITING

Orléans, France
CHU Poitiers
NOT_YET_RECRUITING

Poitiers, 86180, France
CHU de NÎMES - Institut de Cancérologie du Gard
NOT_YET_RECRUITING

Nîmes, 30029, France
CHU de Saint Étienne
RECRUITING

Saint-Etienne, 42270, France
Centre Antoine Lacassagne
RECRUITING

Nice, 06189, France
Centre Eugène Marquis
ACTIVE_NOT_RECRUITING

Rennes, 35042, France
Centre Francois Baclesse
NOT_YET_RECRUITING

Caen, 14000, France
Centre Henri Becquerel
NOT_YET_RECRUITING

Rouen, France
Centre Hospitalier Annecy Genevois
NOT_YET_RECRUITING

Metz-Tessy, France
Centre Hospitalier Départemental de Vendée
NOT_YET_RECRUITING

La Roche-sur-Yon, 85925, France
Centre Hospitalier Métropole de Savoie
ACTIVE_NOT_RECRUITING

Chambéry, 73000, France
Centre Hospitalier Simone Veil de Beauvais
ACTIVE_NOT_RECRUITING

Beauvais, 60021, France
Centre Hospitalier Universitaire de Besancon
NOT_YET_RECRUITING

Besançon, 25000, France
Centre Hospitalier Universitaire de Limoges
ACTIVE_NOT_RECRUITING

Limoges, 87042, France
Centre Hospitalier William Morey
ACTIVE_NOT_RECRUITING

Chalon-sur-Saône, France
Centre Hospitalier d'Auxerre
NOT_YET_RECRUITING

Auxerre, France
Centre Hospitalier de Carcassonne
NOT_YET_RECRUITING

Carcassonne, 11000, France
Centre Hospitalier de Pau
ACTIVE_NOT_RECRUITING

Pau, 64046, France
Centre Hospitalier de Quimper
NOT_YET_RECRUITING

Quimper, 29000, France
Centre Hospitalier de Valence
NOT_YET_RECRUITING

Valence, 26000, France
Centre Hospitalier de Versailles
NOT_YET_RECRUITING

Le Chesnay, 78150, France
Centre Hospitalier de la Cote Basque
ACTIVE_NOT_RECRUITING

Bayonne, 64100, France
Centre Hospitalier le Mans
NOT_YET_RECRUITING

Le Mans, 72000, France
Centre Jean Perrin
NOT_YET_RECRUITING

Clermont-Ferrand, 63011, France
Centre Leon Berard
RECRUITING

Lyon, 69008, France
Centre Paul Stauss
ACTIVE_NOT_RECRUITING

Strasbourg, France
Centre d'Oncologie et de Radiothérapie 37
NOT_YET_RECRUITING

Chambray-lès-Tours, 37170, France
Centre de Cancerologie du Grand Montpellier
RECRUITING

Montpellier, 34070, France
Clinique Mutualiste de l'Estuaire
ACTIVE_NOT_RECRUITING

Saint-Nazaire, 44600, France
Clinique Tivoli
NOT_YET_RECRUITING

Bordeaux, France
Clinique Victor Hugo
NOT_YET_RECRUITING

Le Mans, 72000, France
Clinique de Flandre
NOT_YET_RECRUITING

Coudekerque-Branche, 59210, France
Clinique de l'Europe
NOT_YET_RECRUITING

Amiens, 80090, France
Clinique de la Croix du Sud
NOT_YET_RECRUITING

Quint-Fonsegrives, 31130, France
Complejo Hospitalario Insular Materno-Infantil
RECRUITING

Las Palmas de Gran Canaria, 35016, Spain
Elisabeth Krankenhaus Kassel
NOT_YET_RECRUITING

Kassel, 34117, Germany
Evangelisches Klinikum Gelsenkirchen
NOT_YET_RECRUITING

Gelsenkirchen, 45879, Germany
Frisius MC
NOT_YET_RECRUITING

Leeuwarden, 8934 AD, Netherlands
GZW Hochwaldkrankenhaus
NOT_YET_RECRUITING

Bad Nauheim, 61231, Germany
Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace (GHRMSA)
RECRUITING

Mulhouse, 68100, France
Groupe Hospitalier Rance Emeraude (GHRE)
NOT_YET_RECRUITING

St-Malo, 35400, France
Gustave Roussy
ACTIVE_NOT_RECRUITING

Villejuif, France
Helios Klinikum Berlin Buch
NOT_YET_RECRUITING

Berlin, 13125, Germany
Hopital Diaconesses-Croix Saint Simon
ACTIVE_NOT_RECRUITING

Paris, 75020, France
Hopital Privé du Confluent
NOT_YET_RECRUITING

Nantes, France
Hopital Saint Louis
NOT_YET_RECRUITING

Paris, 75010, France
Hospices Civils de Colmar
ACTIVE_NOT_RECRUITING

Colmar, 68000, France
Hospices Civils de Lyon - Centre principal: Hôpital Lyon Sud
NOT_YET_RECRUITING

Pierre-Bénite, France
Hospital Clínic de Barcelona
RECRUITING

Barcelona, 08036, Spain
Hospital La Fe
RECRUITING

Valencia, 46026, Spain
Hospital Materno-Infantil Málaga
RECRUITING

Málaga, 29011, Spain
Hospital Severo Ochoa
NOT_YET_RECRUITING

Leganés, 28911, Spain
Hospital Son Universitario Son Llatzer
RECRUITING

Palma de Mallorca, 07198, Spain
Hospital Universitari Parc Taulí
RECRUITING

Sabadell, 08208, Spain
Hospital Universitari Sant Joan de Reus
RECRUITING

Reus, 43204, Spain
Hospital Universitario 12 Octubre
NOT_YET_RECRUITING

Madrid, 28041, Spain
Hospital Universitario Arnau de Vilanova de Lleida
RECRUITING

Lleida, 25198, Spain
Hospital Universitario Clínico San Cecilio
RECRUITING

Granada, 18016, Spain
Hospital Universitario Marqués de Valdecilla
RECRUITING

Santander, 39008, Spain
Hospital Universitario Rey Juan Carlos
NOT_YET_RECRUITING

Móstoles, 28933, Spain
Hospital Universitario Son Espases
RECRUITING

Palma de Mallorca, 07120, Spain
Hospital Universitario Virgen de la Arrixaca
RECRUITING

Murcia, 30120, Spain
Hospital Universitario Virgen del Rocio
NOT_YET_RECRUITING

Seville, 41013, Spain
Hospital Universitario de Badajoz
RECRUITING

Badajoz, 06006, Spain
Hospital Universitario de Basurto
NOT_YET_RECRUITING

Bilbao, 48013, Spain
Hospital Universitario de Fuenlabrada
NOT_YET_RECRUITING

Fuenlabrada, 28942, Spain
Hospital Universitario de Jaén
RECRUITING

Jaén, 23007, Spain
Hospital Universitario de Jerez
RECRUITING

Jerez de la Frontera, 11405, Spain
Hospital Vall d'Hebrón
RECRUITING

Barcelona, 08035, Spain
Hospital de Mataró
RECRUITING

Mataró, 08304, Spain
Hospital del Mar
NOT_YET_RECRUITING

Barcelona, 08003, Spain
Hämato-Onklogische Praxis im Medicum
NOT_YET_RECRUITING

Bremen, 28209, Germany
Hämatologie-Onkologie im Zentrum MVZ GmbH
NOT_YET_RECRUITING

Augsburg, 86150, Germany
Hôpital NOVO - Site PONTOISE
NOT_YET_RECRUITING

Pontoise, 95300, France
Hôpital Privé Jean Mermoz
ACTIVE_NOT_RECRUITING

Lyon, 69008, France
Hôpital Privé de la Loire
ACTIVE_NOT_RECRUITING

Saint-Etienne, 42100, France
Hôpital Tenon APHP
NOT_YET_RECRUITING

Paris, 75020, France
Hôpitaux du Léman
ACTIVE_NOT_RECRUITING

Thonon-les-Bains, 74200, France
ICO Hospitalet
RECRUITING

L'Hospitalet de Llobregat, 08908, Spain
IRCCS Centro di Riferimento Oncologico
NOT_YET_RECRUITING

Aviano, 33081, Italy
IRCCS Fondazione Policlinico Universitaria "A. Gemelli"
NOT_YET_RECRUITING

Roma, 00168, Italy
IRCCS Istituto Nazionale dei Tumori Fondazione "G. Pascale"
NOT_YET_RECRUITING

Naples, 80131, Italy
IRCCS Istituto Oncologico Veneto
NOT_YET_RECRUITING

Padova, 32128, Italy
IRCCS Ospedale Policlinico San Martino - Università di Genova
NOT_YET_RECRUITING

Genova, 16132, Italy
InVO - Institut für Versorgungsforschung in der Onkologie
NOT_YET_RECRUITING

Koblenz, 56068, Germany
Institut Bergonie
NOT_YET_RECRUITING

Bordeaux, 33076, France
Institut Claudius Regaud
RECRUITING

Toulouse, 31059, France
Institut Curie
RECRUITING

Saint-Cloud, 92219, France
Institut Curie
RECRUITING

Paris, Île-de-France Region, 75005, France
Institut Jean Godinot
RECRUITING

Reims, 51100, France
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, France
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, Île-de-France Region, 13009, France
Institut de Cancérologie Paris Nord - GCS RISSA
NOT_YET_RECRUITING

Sarcelles, 95200, France
Institut de Cancérologie de Bourgogne
NOT_YET_RECRUITING

Dijon, 21000, France
Institut de Cancérologie de Lorraine
RECRUITING

Vandœuvre-lès-Nancy, France
Institut de Cancérologie de l'Ouest - Site Paul Papin
NOT_YET_RECRUITING

Angers, 49055, France
Institut de Cancérologie de l'Ouest - Site René Gauducheau
NOT_YET_RECRUITING

Saint-Herblain, 44800, France
Klinikum Esslingen GmbH
NOT_YET_RECRUITING

Esslingen am Neckar, 73730, Germany
Klinikum Worms gGmbH
NOT_YET_RECRUITING

Worms, 67550, Germany
Leids Universitair Medisch Centrum (LUMC)
NOT_YET_RECRUITING

Leiden, 2333 ZA, Netherlands
MVZ Medical Center Düsseldorf GmbH
NOT_YET_RECRUITING

Düsseldorf, 40235, Germany
MVZ für Hämatologie und Onkologie Ravensburg GmbH
NOT_YET_RECRUITING

Ravensburg, 88212, Germany
Mammazentrum HH am Krankenhaus Jerusalem
NOT_YET_RECRUITING

Hamburg, 20357, Germany
Medizinische Universität Lausitz - Carl-Thiem
NOT_YET_RECRUITING

Cottbus, 03048, Germany
Nationales Centrum für Tumorerkrankungen
NOT_YET_RECRUITING

Heidelberg, 69120, Germany
Ospedale F. Lotti Pontedera e Volterra, AUSL Toscana Nord Ovest
NOT_YET_RECRUITING

Pontedera, 56125, Italy
Polyclinique Saint Côme
NOT_YET_RECRUITING

Compiègne, 60200, France
Polyclinique de Blois
NOT_YET_RECRUITING

La Chaussée-Saint-Victor, 41260, France
Polyclinique de Limoges - Site Cinique Chénieux
NOT_YET_RECRUITING

Limoges, 87039, France
Praxisklinik Krebsheilkunde für Frauen / Brustzentrum
NOT_YET_RECRUITING

Berlin, 10367, Germany
Rijnstate Ziekenhuis Stichting
NOT_YET_RECRUITING

Arnhem, 6815 AD, Netherlands
Sainte Catherine - Institut du Cancer Avignon Provence
RECRUITING

Avignon, 84918, France
Sana Klinikum Offenbach
NOT_YET_RECRUITING

Offenbach, 63069, Germany
Spaarne Gasthuis Stichting
NOT_YET_RECRUITING

Hoofddorp, 2134 TM, Netherlands
St. Franziskus-Hospital Münster
NOT_YET_RECRUITING

Münster, 48145, Germany
St.-Antonius-Hospital
NOT_YET_RECRUITING

Eschweiler, 52249, Germany
Stichting Viecuri Medisch Centrum voor Noord-Limburg
NOT_YET_RECRUITING

Venlo, 5912 BL, Netherlands
Tergooiziekenhuizen
NOT_YET_RECRUITING

Hilversum, 1212 VG, Netherlands
University Hospital Münster
NOT_YET_RECRUITING

Münster, 48149, Germany
University of Rostock
NOT_YET_RECRUITING

Rostock, 18059, Germany
Universitätsklinikum Aachen AöR
NOT_YET_RECRUITING

Aachen, 52074, Germany
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
NOT_YET_RECRUITING

Dresden, 01307, Germany
Universitätsklinikum Düsseldorf AöR
NOT_YET_RECRUITING

Düsseldorf, 40225, Germany
Universitätsklinikum Leipzig
NOT_YET_RECRUITING

Leipzig, 04103, Germany
Universitätsklinikum Tübingen AöR
NOT_YET_RECRUITING

Tübingen, 72076, Germany
Universitätsklinikum Ulm
NOT_YET_RECRUITING

Ulm, 89075, Germany
Universitätsmedizin Mannheim
NOT_YET_RECRUITING

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.